{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.19","value":"-5.6"},{"groupId":"OG001","spread":"52.65","value":"-43.0"}]}],"title":"SJC (66)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.35","value":"-7.1"},{"groupId":"OG001","spread":"52.77","value":"-41.3"}]}],"title":"SJC (28)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"144.58","value":"7.2"},{"groupId":"OG001","spread":"52.39","value":"-41.8"}]}],"title":"TJC (68)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"195.94","value":"15.7"},{"groupId":"OG001","spread":"63.47","value":"-42.0"}]}],"title":"TJC (28)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.23","value":"-4.2"},{"groupId":"OG001","spread":"39.31","value":"-40.8"}]}],"title":"Physician's global assessment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"44.01","value":"-3.1"},{"groupId":"OG001","spread":"117.90","value":"-25.4"}]}],"title":"Patient's global assessment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.61","value":"2.8"},{"groupId":"OG001","spread":"131.59","value":"-23.8"}]}],"title":"Patient's pain assessment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.46","value":"-2.0"},{"groupId":"OG001","spread":"34.92","value":"-24.3"}]}],"title":"HAQ"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"452.94","value":"80.0"},{"groupId":"OG001","spread":"80.3","value":"-36.3"}]}],"title":"CRP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"95.95","value":"11.4"},{"groupId":"OG001","spread":"59.92","value":"-29.3"}]}],"title":"ESR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"201"},{"groupId":"OG001","value":"298"}],"units":"Participants"}],"description":"Percentage change in the scores of the following parameters of ACR core set relative to respective baseline scores in both study arms was analyzed : SJC (28 and 66 joints) and TJC (28 and 66 joints), patient's global assessment and physician's global assessment based on disease activity (both are expressed by VAS \\[0 = no disease activity to 100 = maximum disease activity\\]), HAQ (based on HAQ disability index \\[HAQDI\\]) which included 8 domains (dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities) rated on a 4-point scale (0=without any difficulty to 3=unable to do), where the sum of scores was divided by the number of domains with a score for a total possible score of 0 (best) to 3 (worst), pain assessment using a VAS ranging from score 0 (no pain) to 100 (unbearable pain), CRP concentration, and ESR.","dispersionType":"Standard Deviation","groups":[{"description":"Eligible participants were administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to 24 weeks and were followed up to Week 104.","id":"OG000","title":"Placebo Plus Methotrexate"},{"description":"Eligible Participants were administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and were followed up to Week 104.","id":"OG001","title":"Rituximab Plus Methotrexate"}],"paramType":"MEAN","populationDescription":"The ITT population included all randomized participants who received any part of an infusion of study drug. Participants whom treatment allocation was unblinded and who received treatment prior to randomization were excluded.","reportingStatus":"POSTED","timeFrame":"From Baseline (Day 1) to Week 24","title":"Percentage Change From Baseline in the ACR Core Set (SJC, TJC, Patient's and Physician's Global Assessments, Health Assessment Questionnaire, Pain, C-Reactive Protein, and Erythrocyte Sedimentation Rate) Score","type":"SECONDARY","unitOfMeasure":"percent change"}